Abstract:Background: Pathological cardiac hypertrophy induced by stresses such as aging and neurohumoral activation is an independent risk factor for heart failure and is considered a target for the treatment of heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. We aimed to investigate the roles of SIRT2 in aging-related and angiotensin II (Ang II)–induced pathological cardiac hypertrophy. Methods: Male C57BL/6J wild-type and Sirt2 knockout mice were subjected to the investigation of aging-related cardiac hypertrophy. Cardiac hypertrophy was also induced by Ang II (1.3 mg/kg/d for 4 weeks) in male C57BL/6J Sirt2 knockout mice, cardiac-specific SIRT2 transgenic ( SIRT2 -Tg) mice, and their respective littermates (8 to ≈12 weeks old). Metformin (200 mg/kg/d) was used to treat wild-type and Sirt2 knockout mice infused with Ang II. Cardiac hypertrophy, fibrosis, and cardiac function were examined in these mice. Results: SIRT2 protein expression levels were downregulated in hypertrophic hearts from mice. Sirt2 knockout markedly exaggerated cardiac hypertrophy and fibrosis and decreased cardiac ejection fraction and fractional shortening in aged (24-month-old) mice and Ang II–infused mice. Conversely, cardiac-specific SIRT2 overexpression protected the hearts against Ang II–induced cardiac hypertrophy and fibrosis and rescued cardiac function. Mechanistically, SIRT2 maintained the activity of AMP-activated protein kinase (AMPK) in aged and Ang II–induced hypertrophic hearts in vivo as well as in cardiomyocytes in vitro. We identified the liver kinase B1 (LKB1), the major upstream kinase of AMPK, as the direct target of SIRT2. SIRT2 bound to LKB1 and deacetylated it at lysine 48, which promoted the phosphorylation of LKB1 and the subsequent activation of LKB1-AMPK signaling. Remarkably, the loss of SIRT2 blunted the response of AMPK to metformin treatment in mice infused with Ang II and repressed the metformin-mediated reduction of cardiac hypertrophy and protection of cardiac function. Conclusions: SIRT2 promotes AMPK activation by deacetylating the kinase LKB1. Loss of SIRT2 reduces AMPK activation, promotes aging-related and Ang II–induced cardiac hypertrophy, and blunts metformin-mediated cardioprotective effects. These findings indicate that SIRT2 will be a potential target for therapeutic interventions in aging- and stress-induced cardiac hypertrophy.

Targeting SIRT2 in Aging-Associated Fibrosis Pathophysiology

Targeting Mitochondrial Sirtuins in Age-Related Neurodegenerative Diseases and Fibrosis

Abstract 186: Impaired Nucleocytoplasmic Shuttling and Activity of SIRT1 in Response to Ischemic Stress in the Senescent Heart

The potential role of senescence in limiting fibrosis caused by aging

SIRT2 Acts As a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.

Abstract 10153: SIRT1 Activation Restores Cardioprotection in the Aged Heart Against Ischemia/Reperfusion Injury

Senescence and tissue fibrosis: opportunities for therapeutic targeting

Renal Fibrosis: SIRT1 Still of Value

The role and regulation of SIRT1 in pulmonary fibrosis

SIRT3: A potential therapeutic target for liver fibrosis

Aryl hydrocarbon receptor: From pathogenesis to therapeutic targets in aging-related tissue fibrosis

SIRT6 in Senescence and Aging-Related Cardiovascular Diseases

The role of Sirtuin 2 in liver - An extensive and complex biological process

SIRT2 counteracts primate cardiac aging via deacetylation of STAT3 that silences CDKN2B

A Troy Horse in Pulmonary Fibrosis

The Senescent Heart—"Age Doth Wither Its Infinite Variety"

Regulation of SIRT1 in aging: Roles in mitochondrial function and biogenesis

Deacetylation of HnRNP U mediated by sirtuin1 ameliorates aged rat with liver fibrosis via inhibiting p53-related senescence and NLRP3-related inflammation

The role of inflammatory and fibrogenic pathways in heart failure associated with aging

Cellular Senescence in Kidney Fibrosis: Pathologic Significance and Therapeutic Strategies

From Microcirculation to Aging-Related Diseases: A Focus on Endothelial SIRT1